Core Insights - Regentis Biomaterials Ltd. has developed a breakthrough manufacturing process for its lead product, GelrinC®, which is designed for treating painful injuries to focal articular knee cartilage [1] - The new manufacturing process is patented in several countries and is pending patent approval in the U.S. [1] - The company is preparing for a commercial launch of GelrinC® in Europe later this year [1] Company Overview - Regentis Biomaterials Ltd. is a regenerative medicine company focused on innovative tissue repair solutions [1] - GelrinC® is an off-the-shelf hydrogel that is synchronized for erosion and is resorbable [1]